Sugi Predict

Sugi Predict / Targets / NUP160

NUP160

Nuclear pore complex protein Nup160 · Q12769 · NUP160 on Sugi Atlas →

0 patent compounds predicted against NUP160, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NUP160 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection PHASE3COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE2NOT_YET_RECRUITING
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination PHASE1/PHASE2COMPLETED
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer PHASE1COMPLETED
Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C nanRECRUITING
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Molecular Mechanism of Nasopharyngeal Carcinoma nanUNKNOWN
Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts nanCOMPLETED
Induced Pluripotent Stem Cells for Niemann Pick Disease nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI nanUNKNOWN
Cluster Randomized Controlled Screening Trial for NPC nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) nanRECRUITING
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging nanUNKNOWN
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure nanRECRUITING
Exome Analysis in Hearing Impaired Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NUP160 binder may also engage these)

ProteinNameSimilarity
Q9Z0W3 — 1.000 Q9Z0W3 →
Q8WUM0 — 0.999 Q8WUM0 →
Q4V9P9 — 0.997 Q4V9P9 →
Q8R0G9 — 0.995 Q8R0G9 →
Q8BJW5 — 0.995 Q8BJW5 →
Q6TNU3 — 0.993 Q6TNU3 →
Q5ZLS8 — 0.993 Q5ZLS8 →
Q3MHH2 — 0.992 Q3MHH2 →
Q6INI5 — 0.992 Q6INI5 →
GSAP Gamma-secretase-activating protein 0.992 landscape →
Q8C3Y4 — 0.992 Q8C3Y4 →
Q5PQS3 — 0.991 Q5PQS3 →
Q5JWR5 — 0.991 Q5JWR5 →
Q9Y3R5 — 0.991 Q9Y3R5 →
Q6ZPR5 — 0.991 Q6ZPR5 →
A0A2R8QPS5 — 0.991 A0A2R8QPS5 →
Q2HJE1 — 0.991 Q2HJE1 →
Q14D04 — 0.991 Q14D04 →
Q5XG71 — 0.991 Q5XG71 →
F4IGA5 — 0.990 F4IGA5 →
Q8K2A7 — 0.990 Q8K2A7 →
Q7TMQ7 — 0.990 Q7TMQ7 →
Q8BKN5 — 0.990 Q8BKN5 →
Q9VKJ3 — 0.990 Q9VKJ3 →
Q3URQ0 — 0.990 Q3URQ0 →
Q9P2D8 — 0.990 Q9P2D8 →
Q9VWE6 — 0.990 Q9VWE6 →
Q5ZM41 — 0.990 Q5ZM41 →
E9PVA8 — 0.989 E9PVA8 →
Q3B8R1 — 0.989 Q3B8R1 →